Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Kura Oncology (KURA) and Vertex Pharmaceuticals (VRTX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bausch Health Companies (BHC – Research Report), Kura Oncology (KURA – Research Report) and Vertex Pharmaceuticals (VRTX – Research Report).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bausch Health Companies (BHC)
RBC Capital analyst Douglas Miehm maintained a Hold rating on Bausch Health Companies today and set a price target of $10.00. The company’s shares closed last Tuesday at $6.16.
According to TipRanks.com, Miehm is a 3-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Bausch Health Companies with a $7.86 average price target, implying a 24.8% upside from current levels. In a report issued on October 7, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a C$9.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Kura Oncology (KURA)
In a report issued on October 20, Jonathan Chang from Leerink Partners reiterated a Buy rating on Kura Oncology. The company’s shares closed last Tuesday at $9.58.
According to TipRanks.com, Chang is a 3-star analyst with an average return of
Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $26.00, which is a 160.3% upside from current levels. In a report issued on October 9, Bank of America Securities also maintained a Buy rating on the stock with a $27.00 price target.
Vertex Pharmaceuticals (VRTX)
In a report issued on October 20, David Risinger from Leerink Partners reiterated a Buy rating on Vertex Pharmaceuticals. The company’s shares closed last Tuesday at $426.27.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vertex Pharmaceuticals with a $490.40 average price target, implying a 17.4% upside from current levels. In a report issued on October 8, J.P. Morgan also maintained a Buy rating on the stock with a $530.00 price target.
Read More on BHC:
Disclaimer & DisclosureReport an Issue
- Bausch Health announces results of special meeting of shareholders
- Bausch Health’s Solta Medical featured on ‘The Balancing Act’
- Bausch Health’s OraPharma introduces ‘OraTalks’ podcast
- Bausch Health completes acquisition of DURECT Corporation
- Solta Medical surpasses 5M skin tightening treatments with Thermage
